Angiopoietin-2 (ANGPT2) and Tyrosine-protein kinase receptor Tie-2 (TIE2) axis (ANGPT2-TIE2)

The Angiopoietin-2–Tyrosine-protein kinase receptor Tie-2 axis is a fundamental signaling pathway that regulates vascular stability, endothelial permeability, and angiogenesis (UniProt: P35916, O15123). Tie2 is a receptor tyrosine kinase primarily expressed on endothelial cells, while Angiopoietin-2 (ANGPT2) acts as a context-dependent antagonist that destabilizes the vasculature by competing with the stabilizing ligand Angiopoietin-1. In pathological conditions such as cancer, neovascular age-related macular degeneration (nAMD), and diabetic macular edema (DME), ANGPT2 is significantly upregulated, leading to vessel leakage, inflammation, and pathological blood vessel growth (Sahara et al., 2017, PMID: 28258200). Therapeutic intervention targeting this axis focuses on neutralizing ANGPT2 or activating Tie2 to restore vascular integrity and "normalize" the blood vessels. For example, Faricimab is a bispecific antibody that inhibits both ANGPT2 and VEGF-A, providing superior anatomical outcomes in retinal diseases compared to VEGF inhibition alone (FDA: Vabysmo Label). Beyond ophthalmology, this axis is a target in oncology to inhibit tumor angiogenesis and in critical care to address the vascular breakdown seen in sepsis (Akil et al., 2019, PMID: 31439717).

Other names

ANG2-TIE2 axisAngiopoietin-2/TEK signaling pathwayANGPT2-TEK axisAngiopoietin-Tie2 system

Neutralization of Angiopoietin-2 to prevent Tie2 antagonism; Activation of the Tie2 receptor to promote vascular stability; Dual inhibition of ANGPT2 and VEGF-A to reduce vascular leakage and pathological angiogenesis (Sahara et al., 2017, PMID: 28258200; FDA: Vabysmo Label).